Top 5 Gynecologic Cancer Stories of February 2026

February brought several important updates in gynecologic cancer care, from new FDA approvals in platinum-resistant ovarian cancer to research examining disparities in clinical trials and a survivor Q&A focused on mental health. Together, these stories reflect both scientific progress and the lived experiences of patients with cancer navigating treatment and survivorship.

Keytruda combination approved for platinum-resistant ovarian cancer

One of the most significant developments was the FDA approval of Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1 (CPS greater than or equal to 1).

The approval was based on results from the phase 3 KEYNOTE-B96 trial, which demonstrated improvements in overall survival and progression-free survival compared with chemotherapy alone. Platinum-resistant ovarian cancer has historically been difficult to treat, and options in this setting are often limited. The addition of an immunotherapy-based regimen offers a new approach for eligible patients and underscores the growing role of biomarker testing in guiding care decisions.

ROSELLA trial extends survival in platinum-resistant ovarian cancer

Another major story centered on results from the phase 3 ROSELLA trial. Investigators found that adding relacorilant to Abraxane (nab-paclitaxel) improved overall survival by 4.1 months compared with chemotherapy alone in patients with platinum-resistant ovarian cancer.

Importantly, the combination did not introduce new side effects beyond those already associated with chemotherapy. Researchers also noted that the regimen does not require biomarker testing, which may allow a broader group of patients to be considered for treatment. The trial introduced a novel strategy targeting the glucocorticoid receptor pathway, offering a different mechanism of action in a space where innovation is urgently needed.

Study reveals racial gaps in advanced ovarian cancer trials

CURE also reported on a cohort study of nearly 1,903 women with stage 3 or stage 4 epithelial ovarian cancer that examined representation and outcomes in clinical trials.

The findings showed that Black and Asian patients were underrepresented in trials. Additionally, Black patients experienced lower overall survival compared with White patients, even within clinical trial settings. Researchers pointed to incomplete or inconsistent reporting of race and ethnicity as a challenge in understanding disparities.

For patients with cancer, the study highlights the importance of equitable trial access and transparent data reporting to ensure that research findings reflect the populations most affected by the disease.

FDA pauses lorigerlimab study after patient death

Safety oversight was another key topic in February. The FDA placed a partial clinical hold on a study evaluating lorigerlimab in certain gynecologic cancers after a patient died from severe neutropenia and septic shock.

The hold pauses new enrollment while safety data are reviewed. Patients already participating in the study may continue receiving treatment. The development underscores the critical role of monitoring and regulatory review in protecting patients enrolled in clinical trials, particularly in studies involving novel immunotherapy combinations.

Survivor Q&A highlights mental health and self-advocacy

Beyond clinical data, CURE featured a Q&A with a gynecologic cancer survivor who shared insights about trusting her instincts and protecting her mental health during and after treatment.

In the conversation, she discussed the emotional weight of diagnosis and ongoing care, emphasizing the importance of listening to one’s body, asking questions and advocating for oneself. She also spoke about prioritizing psychological well-being and seeking support when needed.

For patients with cancer and caregivers, the Q&A served as a reminder that cancer care extends beyond physical treatment. Emotional health, communication with care teams and self-advocacy remain central to navigating the complexities of gynecologic cancer.

Together, these five stories reflect progress in treatment approvals, innovation in clinical research, continued attention to equity and the personal experiences that shape cancer care every day.

References

1. “FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.” FDA. Feb 10, 2026.
2. “Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma” by Dr. Caitlin Ruth Johnson, et al., JAMA Network Open.
3. “Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study.” BioSpace. News Release.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.